Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-18T01:45:04.362Z Has data issue: false hasContentIssue false

Modeling the Impact of Anticancer Agents on MetastaticSpreading

Published online by Cambridge University Press:  25 January 2012

S. Benzekry
Affiliation:
CMI-LATP, UMR 6632, Université de Provence, Technopôle Château-Gombert 39, rue F. Joliot-Curie, 13453 Marseille cedex 13, FranceLaboratoire de Toxicocinétique et Pharmacocinétique UMR INSERM 911, CRO2 27, boulevard Jean Moulin, 13005 Marseille, France
N. André
Affiliation:
Service d’Hématologie et Oncologie Pédiatrique, Hôpital pour enfants de La Timone Marseille, FranceMetronomics Global Health Initiative
A. Benabdallah
Affiliation:
CMI-LATP, UMR 6632, Université de Provence, Technopôle Château-Gombert 39, rue F. Joliot-Curie, 13453 Marseille cedex 13, France
J. Ciccolini
Affiliation:
Laboratoire de Toxicocinétique et Pharmacocinétique UMR INSERM 911, CRO2 27, boulevard Jean Moulin, 13005 Marseille, France
C. Faivre
Affiliation:
Laboratoire de Toxicocinétique et Pharmacocinétique UMR INSERM 911, CRO2 27, boulevard Jean Moulin, 13005 Marseille, France
F. Hubert
Affiliation:
CMI-LATP, UMR 6632, Université de Provence, Technopôle Château-Gombert 39, rue F. Joliot-Curie, 13453 Marseille cedex 13, France
D. Barbolosi*
Affiliation:
Laboratoire de Toxicocinétique et Pharmacocinétique UMR INSERM 911, CRO2 27, boulevard Jean Moulin, 13005 Marseille, France
*
⋆Corresponding author. E-mail: fhubert@cmi.univ-mrs.fr

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Treating cancer patients with metastatic disease remains an ultimate challenge inclinical oncology. Because invasive cancer precludes or limits the use of surgery,metastatic setting is often associated with (poor) survival, rather than sustainedremission, in patients with common cancers like lung, digestive or breast carcinomas.Mathematical modeling may help us better identify non detectable metastatic status to inturn optimize treatment for patients with metastatic disease. In this paper we present afamily of models for the metastatic growth. They are based on four principles : to be assimple as possible, involving the least possible number of parameters, the maininformations are obtained from the primary tumor and being able to recover the variety ofphenomena observed by the clinicians. Several simulations of therapeutic strategies arepresented illustrating possible applications of modeling to the clinic.

Information

Type
Research Article
Copyright
© EDP Sciences, 2012